Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.

Abstract

BACKGROUND Recently a new 'all in one' single capsule with the three components of bismuth-based triple therapy became available in trials for treating Helicobacter pylori. AIM To investigate the efficacy and tolerability of this new capsule when combined with lansoprazole. METHODS A total of 66 consecutive infected patients from a single centre received two single triple capsules four times daily and lansoprazole 30 mg b.d. for 7 days. Each capsule contained 60 mg of bismuth subcitrate, 125 mg of tetracycline and 125 mg of metronidazole. Endoscopy with biopsies for CLO-test, histology and culture from antrum and corpus was performed before and at least 5 weeks after treatment. RESULTS The per protocol cure rate was 56/64 (88%, 95% CI: 79-95%); by intention-to-treat 56/65 (86%, 95% CI: 78-95%). The per protocol cure rate in metronidazole sensitive strains was 40/43 (93%, 95% CI: 85-100%); in resistant strains 5/9 (56%, 95% CI: 23-88%). There was one drop-out due to adverse events. CONCLUSIONS It is possible to combine the components of bismuth-based triple therapy into a single capsule. Based on the results it can be assumed that the capsule releases its content in the stomach. When combined with lansoprazole it reaches high cure rates, especially in metronidazole sensitive strains. This new approach simplifies bismuth-based anti-Helicobacter therapy.

Statistics

010002000'04'06'08'10'12'14'16
Citations per Year

697 Citations

Semantic Scholar estimates that this publication has 697 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Boer2000BismuthbasedQT, title={Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.}, author={Wink A de Boer and Robert Jan van Etten and B A van de Wouw and Peter Martin Schneeberger and Arnoud H A M van Oijen and Jan B. M. J. Jansen}, journal={Alimentary pharmacology & therapeutics}, year={2000}, volume={14 1}, pages={85-9} }